Lung Cancer Clinical Trials in Houston

Showing 381-400 of 620 trials

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

NCT03965845

This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.

Solid TumorsNSCLCCRC+1 more

Calithera Biosciences, Inc53 participantsStarted Jun 2019

Santa Monica, California, United States • Atlanta, Georgia, United States • Chicago, Illinois, United States +7 more locations

TERMINATEDNA< 1 mile

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

NCT04862195

This is a non-significant risk, double-blinded, randomized, registrational study to compare the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™) in reducing cancer-related anxiety and depression symptoms when used adjunctively with multidisciplinary (medical, psychosocial) oncology usual care regimens for up to 10 weeks. Study population will consist of up to 553 participants with stage I-III breast cancer or stage I-III NSCLC. The primary endpoint is percent improvement in anxiety symptoms at Week 10 and secondary endpoints of percent improvement in depressive symptoms will be assessed at Week 12. An interim analysis for efficacy and futility will be conducted once 236 participants have completed the study.

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more

Blue Note Therapeutics31 participantsStarted May 2021

Glendale, California, United States • Los Alamitos, California, United States • Redlands, California, United States +10 more locations

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Lung Cancer Trials in Other Cities

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

A Study of PLX2853 in Advanced Malignancies.

A Study of APG-1252 in Patients With SCLC or Other Solid Tumors

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

A Study of LY3023414 in Participants With Advanced Cancer

PEN-866 in Patients With Advanced Solid Malignancies

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Safety Study of MGA271 in Refractory Cancer

Other Conditions in Houston